Table 3. Comparison of differences in CHADS2 with warfarin and antiplatelet therapy between sexes (n = 1776).
| CHADS2-VASc | 0 (n = 425, %) | 1–2 (n = 234, %) | >2 (n = 1117, %) | P | |||
|---|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | - | |
| Warfarin alone | 74 (4.1) | - | 78 (4.4) | 74 (4.1) | 156 (8.7) | 553 (31.1) | <.001 |
| Dual therapy | 11 (0.6) | - | 27 (1.5) | 7 (0.4) | 106 (5.9) | 128 (7.2) | .001 |
| Triple therapy | 1 | - | 1 | - | 19 (1.0) | 15 (0.8) | .002 |
| Antiplatelet | 288 (16.2) | - | 11 (0.6) | 3 (0.1) | 35 (1.9) | 49 (2.7) | NS |
| None | 51 (2.8) | - | 16 (0.9) | 17 (0.9) | 22 (1.2) | 34 (1.9) | .030 |
Key: CHADS2: Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke/TIA2. Dual therapy: warfarin and either of the two antiplatelets (aspirin or clopidogrel). Triple therapy: warfarin plus aspirin plus clopidogrel. Antiplatelet: aspirin or clopidogrel or both. None: neither warfarin nor antiplatelet. NS: not significant, 1784 completed the follow-up.